TODO: Skip to main content
Top
Gepubliceerd in:

01-04-2014 | Original Paper

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

Auteurs: Craig A. Erickson, Jeremy M. Veenstra-Vanderweele, Raun D. Melmed, James T. McCracken, Lawrence D. Ginsberg, Linmarie Sikich, Lawrence Scahill, Maryann Cherubini, Peter Zarevics, Karen Walton-Bowen, Randall L. Carpenter, Mark F. Bear, Paul P. Wang, Bryan H. King

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 4/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.
Literatuur
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.
Metagegevens
Titel
STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
Auteurs
Craig A. Erickson
Jeremy M. Veenstra-Vanderweele
Raun D. Melmed
James T. McCracken
Lawrence D. Ginsberg
Linmarie Sikich
Lawrence Scahill
Maryann Cherubini
Peter Zarevics
Karen Walton-Bowen
Randall L. Carpenter
Mark F. Bear
Paul P. Wang
Bryan H. King
Publicatiedatum
01-04-2014
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 4/2014
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-013-1963-z